Look back at pharma news in the week to March 19, 2021

21 March 2021

By Barbara Obstoj-Cardwell. Editor

Among last week’s notable research news, Eli Lilly presented updated results on its Alzheimer’s disease candidate donanemab which, though touted as promising in a disease area that has been filled with failures, is seen as disappointing by some. Meantime, strong Phase III results saw Sanofi and partner Regeneron Pharmaceuticals halt their trial of Libtayo in cervical cancer. On the deal-making front, rivals in the HIV space Gilead Sciences and Merck & Co signed a pact last Monday to trial a combination of their respective candidates – lenacapavir and islatravir. Regulatory news saw AbbVie suffer a setback last Wednesday, when the US Food and Drug Administration extended the review period for its Rinvoq in the treatment of active psoriatic arthritis.

Lilly’s donanemab has much to prove

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK